论文信息 - A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design - 字舞流文

A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients (NCI 10327): Rationale and Study Design

Ian R. Lanza | S. Cherry | L. Nardo | J. Riess | D. Gandara | D. Shackelford | P. Frankel | M. Dunphy | P. Lara | C. Kunos | J. Reid | I. Lanza | E. Newman | D. Ramsey | Badawi | I. Wilson | Gonsalves | Paul | K. Paik